Additional file 1 of Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD

Additional file 1: Fig S1. Ibrutinib, PD180970, and cabozantinib do not alter tau phosphorylation at residue Thr231 in the hippocampal CA1 region in 3.5- to 4-month-old 5xFAD mice. A Immunofluorescence staining of AT180 in brain slices from 5xFAD mice injected daily with vehicle (10% DMSO+40% PEG300+5% Tween80+45% saline), ibrutinib (10 mg/kg, i.p.), PD180970 (10 mg/kg, i.p.), or cabozantinib (10 mg/kg, i.p.) for 14 consecutive days. B Quantification of data from A (n=15–19 brain slices from 3–5 mice/group). Scale bar=100 μm. Fig S2. PD180970 upregulates the tau kinase DYRK1A in the hippocampal CA1 region in 3.5- to 4-month-old 5xFAD mice. A Immunofluorescence staining of DYRK1A in brain slices from 5xFAD mice injected daily with vehicle (10% DMSO+40% PEG300 + 5% Tween80 + 45% saline), ibrutinib (10 mg/kg, i.p.), PD180970 (10 mg/kg, i.p.), or cabozantinib (10 mg/kg, i.p.) for 14 consecutive days. B Quantification of data from A (n=19-20 brain slices from 4–5 mice/group). *p<0.05, **p